{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T10:16:41Z","timestamp":1648981001239},"reference-count":63,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1016\/j.medcli.2013.01.039","type":"journal-article","created":{"date-parts":[[2013,3,27]],"date-time":"2013-03-27T03:42:50Z","timestamp":1364355770000},"page":"306-313","source":"Crossref","is-referenced-by-count":0,"title":["Nuevos f\u00e1rmacos antituberculosos en la tuberculosis resistente y multirresistente"],"prefix":"10.1016","volume":"141","author":[{"given":"Marta","family":"Ram\u00edrez Lapausa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Francisco","family":"Pascual Pareja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arturo","family":"Noguerado Asensio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10 Suppl 2","key":"10.1016\/j.medcli.2013.01.039_bib0005","first-page":"S231","article-title":"Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units 1946-1986, with relevant subsequent publications","volume":"3","author":"Fox","year":"1999","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.medcli.2013.01.039_bib0010","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S1473-3099(09)70041-6","article-title":"Treatment outcomes among patients with multidrug-resistant tuberculosis: Systematic review and meta-analysis","volume":"9","author":"Orenstein","year":"2009","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.medcli.2013.01.039_bib0015","doi-asserted-by":"crossref","first-page":"e6914","DOI":"10.1371\/journal.pone.0006914","article-title":"Treatment outcomes of multidrug-resistant tuberculosis: A systematic review and meta-analysis","volume":"4","author":"Johnston","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.medcli.2013.01.039_bib0020","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1086\/653115","article-title":"Treatment outcomes among patients with extensively drug-resistant tuberculosis: Systematic review and meta-analysis","volume":"51","author":"Jacobson","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medcli.2013.01.039_bib0025","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1183\/09031936.00145411","article-title":"Alarming levels of drug-resistant tuberculosis in Belarus: Results of a survey in Minsk","volume":"39","author":"Skrahina","year":"2012","journal-title":"Eur Respir J"},{"key":"10.1016\/j.medcli.2013.01.039_bib0030","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1183\/09031936.00073611","article-title":"WHO guidelines for the programmic management of drug-resistant tuberculosis. 2011 update","volume":"38","author":"Falzon","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1016\/j.medcli.2013.01.039_bib0035","first-page":"139","article-title":"A randomised controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistan tuberculosis","volume":"12","author":"Katiyar","year":"2008","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.medcli.2013.01.039_bib0040","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S1473-3099(10)70139-0","article-title":"Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis","volume":"10","author":"Caminero","year":"2010","journal-title":"Lancet Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.medcli.2013.01.039_bib0045","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1016\/S1472-9792(08)70038-6","article-title":"The early bactericidal activity of anti-tuberculosis drugs: A literature review","volume":"88","author":"Donald","year":"2008","journal-title":"Tuberculosis (Edinb)"},{"key":"10.1016\/j.medcli.2013.01.039_bib0050","first-page":"164","article-title":"Investigation of cross-resistance between rifampin and rifabutin in Mycobacterium tuberculosis complex strains","volume":"6","author":"Uzun","year":"2002","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.medcli.2013.01.039_bib0055","unstructured":"Centers for Disease Control and Prevention. High dose rifapentine pharmacokinetics, tolerability and safety dosage rifapentine for treatment of tuberculosis (TBTC-29PK) [ClinicalTrials.gov identifier NCT01043575]. US. National Institutes of Health, ClinicalTrials.gov [online] [consultado 28 Jun 2010]. Disponible en: http:\/\/www.clinicaltrials.gov"},{"key":"10.1016\/j.medcli.2013.01.039_bib0060","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1089\/mdr.2006.12.7","article-title":"Stepwise decrease in moxifloxacin susceptibility amongst clinical isolates of multidrug-resistant Mycobacterium tuberculosis: Correlation with ofloxacin susceptibility","volume":"12","author":"Kam","year":"2006","journal-title":"Microb Drug Resist"},{"issue":"Supl 1","key":"10.1016\/j.medcli.2013.01.039_bib0065","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0213-005X(11)70018-0","article-title":"New drugs for tuberculosis treatment","volume":"29","author":"S\u00e1nchez","year":"2011","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.medcli.2013.01.039_bib0070","first-page":"605","article-title":"Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis","volume":"10","author":"Johnson","year":"2006","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.medcli.2013.01.039_bib0075","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S1473-3099(03)00671-6","article-title":"Fluoroquinolones, tuberculosis, and resistance","volume":"3","author":"Ginsburg","year":"2003","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.medcli.2013.01.039_bib0080","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1128\/AAC.01036-07","article-title":"Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis","volume":"52","author":"Peloquin","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medcli.2013.01.039_bib0085","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.5588\/ijtld.12.0277","article-title":"New drugs for the treatment of tuberculosis: Hope and reality","volume":"16","author":"Grosset","year":"2012","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.medcli.2013.01.039_bib0090","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0140-6736(09)60333-0","article-title":"Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: A double-blind, randomised, controlled phase ii trial","volume":"373","author":"Conde","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.medcli.2013.01.039_bib0095","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/S0140-6736(10)60359-9","article-title":"Global tuberculosis drug development pipeline: The need and the reality","volume":"375","author":"Ma","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.medcli.2013.01.039_bib0100","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1164\/rccm.201001-0077OC","article-title":"Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis","volume":"182","author":"Van Deun","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.medcli.2013.01.039_bib0105","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1056\/NEJMoa055191","article-title":"Outpatient gatifloxacin therapy and dysglycemia in older adults","volume":"354","author":"Park-Wyllie","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2013.01.039_bib0110","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1177\/1753465812452193","article-title":"New treatment options for multidrug-resistant tuberculosis","volume":"6","author":"Field","year":"2012","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.medcli.2013.01.039_bib0115","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1164\/rccm.200806-892OC","article-title":"Early and extended early bacterial activity of linezolid in pulmonary tuberculosis","volume":"178","author":"Dietze","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.medcli.2013.01.039_bib0120","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1086\/648675","article-title":"Linezolid in the treatment of multidrug-resistant tuberculosis","volume":"50","author":"Schecter","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medcli.2013.01.039_bib0125","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1183\/09031936.00009509","article-title":"A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis","volume":"34","author":"Migliori","year":"2009","journal-title":"Eur Respir J"},{"key":"10.1016\/j.medcli.2013.01.039_bib0130","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1128\/AAC.47.1.416-417.2003","article-title":"In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis that are susceptible or resistant to first-line antituberculous drugs","volume":"47","author":"Alcal\u00e1","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medcli.2013.01.039_bib0135","doi-asserted-by":"crossref","first-page":"447","DOI":"10.5588\/ijtld.11.0451","article-title":"Linezolid for the treatment of complicated drug-resistant tuberculosis: A systematic review and meta-analysis","volume":"16","author":"Cox","year":"2012","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.medcli.2013.01.039_bib0140","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1056\/NEJMoa1201964","article-title":"Linezolid for treatment of chronic extensively drug-resistant tuberculosis","volume":"367","author":"Lee","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2013.01.039_bib0145","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1128\/AAC.01189-07","article-title":"In vitro-selected linezolid-resistant Mycobacterium tuberculosis mutants","volume":"52","author":"Hillemann","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medcli.2013.01.039_bib0150","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1183\/09031936.00022912","article-title":"Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: Systematic review and meta-analysis","volume":"40","author":"Sotgiu","year":"2012","journal-title":"Eur Respir J"},{"issue":"Suppl 1","key":"10.1016\/j.medcli.2013.01.039_bib0155","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1016\/S0163-4453(09)60009-8","article-title":"Linezolid: A review of safety and tolerability","volume":"59","author":"Vinh","year":"2009","journal-title":"J Infect"},{"key":"10.1016\/j.medcli.2013.01.039_bib0160","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.medcli.2011.10.029","article-title":"Evoluci\u00f3n y tratamiento de pacientes con tuberculosis multirresistente","volume":"138","author":"Ram\u00edrez Lapausa","year":"2012","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.medcli.2013.01.039_bib0165","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1093\/jac\/dkh405","article-title":"Reversal of linezolid-associated cytopenias, but not peripheral neuropathy, by administration of vitamin B6","volume":"54","author":"Spellberg","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.medcli.2013.01.039_bib0170","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1128\/AAC.43.5.1189","article-title":"Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model","volume":"43","author":"Cynamon","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medcli.2013.01.039_bib0175","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1749-6632.2011.06330.x","article-title":"The oxazolindiones: Past, present, and future","volume":"1241","author":"Saw","year":"2011","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.medcli.2013.01.039_bib0180","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1164\/rccm.200904-0611OC","article-title":"Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis","volume":"180","author":"Williams","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.medcli.2013.01.039_bib0185","doi-asserted-by":"crossref","first-page":"849","DOI":"10.2217\/fmb.10.50","article-title":"TMC207: The first compound of a new class of potent antituberculosis drugs","volume":"5","author":"Matteelli","year":"2010","journal-title":"Future Microbiol"},{"key":"10.1016\/j.medcli.2013.01.039_bib0190","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1126\/science.1106753","article-title":"A diarylquinoline drug active on ATP synthase of Mycobacterium tuberculosis","volume":"307","author":"Andries","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.medcli.2013.01.039_bib0195","doi-asserted-by":"crossref","first-page":"4202","DOI":"10.1128\/AAC.00181-07","article-title":"In vitro antimycobacterial spectrum of a diarylquinoline ATP synthase inhibitor","volume":"51","author":"Huitric","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medcli.2013.01.039_bib0320","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/QAI.0b013e3182410503","article-title":"Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study A5267","volume":"59","author":"Dooley","year":"2012","journal-title":"J Acquir Inmune Defic Syndr"},{"key":"10.1016\/j.medcli.2013.01.039_bib0205","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S0140-6736(12)61080-0","article-title":"14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: A randomised trial","volume":"380","author":"Diacon","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.medcli.2013.01.039_bib0210","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1128\/AAC.01204-07","article-title":"Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis","volume":"52","author":"Rustomjee","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medcli.2013.01.039_bib0215","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1056\/NEJMoa0808427","article-title":"The diarylquinoline TMC207 for multidrug-resistant tuberculosis","volume":"360","author":"Diacon","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2013.01.039_bib0220","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1128\/AAC.06126-11","article-title":"Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: Long-term outcome, tolerability, and effect on emergence of drug resistance","volume":"56","author":"Diacon","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medcli.2013.01.039_bib0225","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.2165\/11538170-000000000-00000","article-title":"Drugs in development for tuberculosis","volume":"70","author":"Ginsberg","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.medcli.2013.01.039_bib0230","doi-asserted-by":"crossref","first-page":"e466","DOI":"10.1371\/journal.pmed.0030466","article-title":"OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice","volume":"3","author":"Matsumoto","year":"2006","journal-title":"PLoS Med"},{"key":"10.1016\/j.medcli.2013.01.039_bib0235","doi-asserted-by":"crossref","first-page":"949","DOI":"10.5588\/ijtld.10.0616","article-title":"Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients","volume":"15","author":"Diacon","year":"2011","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.medcli.2013.01.039_bib0240","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1056\/NEJMoa1112433","article-title":"Delamanid for multidrug-resistant pulmonary tuberculosis","volume":"366","author":"Gler","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2013.01.039_bib0245","article-title":"Delamanid improves outcomes and reduces mortality for multidrug-resistant tuberculosis","author":"Skripconoka","year":"2012","journal-title":"Eur Respir J"},{"key":"10.1016\/j.medcli.2013.01.039_bib0250","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1128\/AAC.49.6.2289-2293.2005","article-title":"Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis","volume":"49","author":"Tyagi","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medcli.2013.01.039_bib0255","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1128\/AAC.00074-08","article-title":"Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis","volume":"52","author":"Nuermberger","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medcli.2013.01.039_bib0260","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1128\/AAC.00112-09","article-title":"Assessment of the effects of the nitroimidazo-oxazine PA-824 on renal function in healthy subjects","volume":"53","author":"Ginsberg","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medcli.2013.01.039_bib0265","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1128\/AAC.01326-06","article-title":"Drug therapy of experimental tuberculosis (TB): Improved outcome by combining SQ109, a new diamine antibiotic, with existing TB drugs","volume":"51","author":"Nikonenko","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medcli.2013.01.039_bib0270","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1093\/jac\/dkl227","article-title":"Synergistic interactions of SQ109, a new ethylene diamine, with front-line antitubercular drugs in vitro","volume":"58","author":"Chen","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.medcli.2013.01.039_bib0275","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1128\/AAC.01601-09","article-title":"In vitro interactions between new antitubercular drug candidates SQ109 and TMC207","volume":"54","author":"Reddy","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medcli.2013.01.039_bib0280","series-title":"45th IDSA Annual Meeting","article-title":"Phase 1 safety and pharmacokinetics of SQ109, a new diamine antituberculosis drug [abstract]","author":"Horwith","year":"2007"},{"key":"10.1016\/j.medcli.2013.01.039_bib0285","unstructured":"National Institute of Allergy and Infectious Diseases (NIAID). Dose escalation study of SQ109 in healthy adult Volunteers [ClinicalTrials.gov identifier NCT00866190]. US National Institutes of Health, ClinicalTrials.gov [online] [consultado 28 Jun 2010]. Disponible en: http:\/\/www.clinicaltrials.gov"},{"key":"10.1016\/j.medcli.2013.01.039_bib0290","first-page":"51","article-title":"Drug-resistant tuberculosis: Emerging treatment options","volume":"3","author":"Adhvaryu","year":"2011","journal-title":"Clin Pharmacol"},{"key":"10.1016\/j.medcli.2013.01.039_bib0295","unstructured":"Clinical Trials Registry, India. CTRI\/2009\/091\/000741 [consultado 26 Jun 2011]. Disponible en: http:\/\/www.ctri.nic.in\/Clinicaltrials\/pmaindet2.php?trialid=922"},{"key":"10.1016\/j.medcli.2013.01.039_bib0300","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.mib.2011.07.022","article-title":"New tuberculosis drugs on the horizon","volume":"14","author":"Cole","year":"2011","journal-title":"Curr Opin Microbiol"},{"key":"10.1016\/j.medcli.2013.01.039_bib0305","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1128\/AAC.01676-09","article-title":"Clinical isolates of Mycobacterium tuberculosis in four European hospitals are uniformly susceptible to benzothiazinones","volume":"54","author":"Pasca","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medcli.2013.01.039_bib0310","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1128\/AAC.01666-10","article-title":"In vitro and in vivo profiles of ACH-702, an isothiazoloquinolone, against bacterial pathogens","volume":"55","author":"Pucci","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medcli.2013.01.039_bib0315","doi-asserted-by":"crossref","first-page":"5185","DOI":"10.1128\/AAC.00699-11","article-title":"Clofaziminane analogs with efficacy against experimental tuberculosis and reduced potencial for accumulation","volume":"55","author":"Lu","year":"2011","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775313001243?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775313001243?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,11]],"date-time":"2019-07-11T11:34:59Z","timestamp":1562844899000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775313001243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":63,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S0025775313001243"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2013.01.039","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]}}}